Therapeutic peptides
AssigneesShape Therapeutics Inc., The Regents of the University of California
InventorsPrashant Mali, Sami Nourreddine, Daihua Chen, Rafael Ponce
Life of this patent
Estimating the term…
Abstract
Disclosed herein are engineered peptides for treatment of diseases or conditions such as cancer. Also disclosed herein are pharmaceutical compositions containing engineered peptides of the present disclosure. Also disclosed herein are methods of treating a disease or condition by administering an engineered peptide of the present disclosure. Also disclosed herein are methods of making engineered peptides described herein.
Claims21
1-40. (canceled)
An engineered peptide having at least about 84% sequence identity to SEQ ID NO:
- 1, SEQ ID NO:2, or SEQ ID NO:3.
An engineered peptide or a salt thereof comprising at least 85% sequence identity to a contiguous portion of an RB1 peptide, a CHEK2 peptide, an MDM2 peptide, a RAF1 peptide, an RRAS2 peptide, a RAC1 peptide, a PIK3Ca peptide, a PIK3R1 peptide, a VHL peptide, a DDX3X peptide, or a CTNNB1 peptide;
- wherein the contiguous portion comprises from about 10 amino acids to about 20 amino acids.
A method of making engineered therapeutic peptides for treatment of cancer, the method comprising:
- (a) selecting portions of a candidate polypeptide that display cellular toxicity, as determined in an in vitro assay;
- (b) curating the portions of the candidate polypeptides to select a subset of the portions of the candidate polypeptide that adopt an alpha helical structure, as determined by x-ray crystallography;
- (c) modifying the subset using mutagenesis to generate engineered therapeutic peptides, and
- (d) selecting engineered therapeutic peptides having an IC50 of from about 1 nM to about 50 μM against a cancer cell line, as determined in an in vitro assay.
Dependencies are inferred from the claim text.